Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Health Canada has approved Paladin Labs' Seasonique, a next generation extended-cycle oral contraceptive for the prevention of pregnancy.
Subscribe to our email newsletter
Seasonique is manufactured by Duramed Pharmaceuticals, a wholly owned subsidiary of Teva Pharmaceutical Industries.
Under the Seasonique extended-cycle regimen, women take active tablets of 0.15mg levonorgestrel/0.03mg of ethinyl estradiol for 84 consecutive days, followed by seven days of a low dose of ethinyl estradiol (0.01mg).
Paladin Labs said that the regimen is designed to reduce the number of withdrawal bleeding periods from thirteen to four periods per year.
Jonathan Ross Goodman, president and CEO at Paladin Labs, said: “The approval of Seasonique is great news for Canadian women. Now women have an additional extended-cycle oral contraceptive from which to reduce the number of menstruations from thirteen to four per year.”
Paladin Labs is a Canada-based specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products.